GlobalData on MSN16h
Travere takes rare disease kidney drug to FDA despite failed trialTravere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback